Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression
Astrid De Boeck, Bo Young Ahn, Charlotte D’Mello, Xueqing Lun, Shyam V. Menon, Mana Alshehri, Frank Szulzewsky, Yaoqing Shen, Lubaba Khan, Ngoc Ha Dang, Elliott Michael Reichardt, Kimberly-Ann R. Goring, Jennifer C. King, Cameron J. Grisdale, Natalie Grinshtein, Dolores Hambardzumyan, Karlyne M. Reilly, Michael Blough, J. Gregory Cairncross, V. Wee Yong, Marco A. Marra, Steven J.M. Jones, David R. Kaplan, Kathy D. McCoy, Eric C. Holland, Pinaki Bose, Jennifer A. Chan, Stephen M. Robbins, Donna L. Senger
Abstract
Despite a deeper molecular understanding, human glioblastoma remains one of the most treatment refractory and fatal cancers. It is known that the presence of macrophages and microglia impact glioblastoma tumorigenesis and prevent durable response. Herein we identify the dual function cytokine IL-33 as an orchestrator of the glioblastoma microenvironment that contributes to tumorigenesis. We find that IL-33 expression in a large subset of human glioma specimens and murine models correlates with increased tumor-associated macrophages/monocytes/microglia. In addition, nuclear and secreted functions of IL-33 regulate chemokines that collectively recruit and activate circulating and resident innate immune cells creating a pro-tumorigenic environment. Conversely, loss of nuclear IL-33 cripples recruitment, dramatically suppresses glioma growth, and increases survival. Our data supports the paradigm that recruitment and activation of immune cells, when instructed appropriately, offer a therapeutic strategy that switches the focus from the cancer cell alone to one that includes the normal host environment.